Test Developers Discuss Challenges of Validating NGS Panels; Pros and Cons of FDA-cleared Products | GenomeWeb

SAN FRANCISCO (GenomeWeb) – Developers of next-generation sequencing-based tests said this week that despite improvements to sequencing technology, there are still significant challenges in developing clinical NGS-based gene panels.

These challenges include, but go beyond, the sequencing technology itself, and include differences in laboratories' bioinformatics pipelines, DNA extraction and sample prep protocols, as well as differences in the sample itself.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.